Abstract
Drug shortages have been troubling the oncology community for more than 2 years. But in a study published in The New England Journal of Medicine in late 2012, we received the first proof that drug substitution can most definitely lead to poorer outcomes for our patients. Editor-in-chief Pamela Hallquist Viale reports on this significant study and its sobering implications.
